论文部分内容阅读
随着临床上对腔隙性脑梗死纯运动性轻偏瘫(pure motor hemiparesis,PMH)治疗效果的不断重视,应用益红抗脑栓胶囊治疗得到进一步效果。对PMH的治疗主要是依靠对病因的彻底探讨,根据治疗原则来确定其临床价值。该研究通过对浙江省奉化市人民医院2013年3月—2014年9月178例腔隙性脑梗死纯运动性轻偏瘫病患分别采用益红抗脑栓胶囊和脉栓通胶囊治疗,对治疗后的有效性及血液流变学指标进行对比。最后发现益红抗脑栓胶囊在应用过程中安全性高,治疗的有效性比例更大。并且有利于血脂和血液流变学指标的稳定,对神经功能的修复作用更大。因此,临床上应推广应用益红抗脑栓胶囊治疗PMH。但药物之间的总体的差异还需进一步对比,以保证临床疗效。
With the continuous attention to the therapeutic effect of pure motor hemiparesis (PMH) in patients with lacunar infarction, the application of Yihong Anti-bolt Capsule has further effect. The treatment of PMH depends mainly on the thorough investigation of the cause, according to the principle of treatment to determine its clinical value. The study adopted Fengyi anti-cerebral thrombosis capsule and vein thrombosis capsule treatment of 178 patients with pure motor hemiparesis lacunar infarction from March 2013 to September 2014 in Fenghua People’s Hospital of Zhejiang Province. After the effectiveness and hemorheology indicators were compared. Finally found that the benefits of anti-cerebral thrombosis capsules in the application of high safety, the treatment of a greater proportion of the effectiveness. And is conducive to the stability of blood lipid and blood rheology indicators, the greater the repair of nerve function. Therefore, the clinical application of Yihong anti-cerebral thrombosis capsules should be the treatment of PMH. However, the overall differences between drugs need to be further compared to ensure the clinical efficacy.